Chronic Kidney Disease
Conditions
Keywords
CKD, bedtime dosing, isolated nocturnal hypertension
Brief summary
Isolated nocturnal hypertension (INH) has been studied among the general population and hypertensive patients. However, little insight is available on the prognostic effect of INH in patients with chronic kidney disease (CKD). This study investigated the prognostic effect of INH in a cohort of Chinese patients with nondialysis CKD.
Detailed description
Patients with or without isolated nocturnal hypertension will be enrolled in this study, and the patients with isolated nocturnal hypertension will be randomly divided into two groups and treated with bedtime or awakening doses of potassium losartan. Any patients who had any antihypertension medication at bedtime would withdrawal the drugs for 2 weeks before ABPM. Patients with isolated nocturnal hypertension will be randomly divided into two groups and received a bedtime or awakening dose of potassium losartan.
Interventions
treated with bedtime or awakening doses of potassium losartan
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* daytime BP \<135/85mmHg，nighttime BP≥120/70mmHg；； * presence of CKD; * estimated GFR (eGFR)\<90 mL⁄ min ⁄ 1.73 m2 (using the Modification of Diet in Renal Disease Study equation) but \>30 mL⁄ min ⁄1.73 m2; * signed informed consent from participating patients.
Exclusion criteria
* pregnancy; * tumor; * infection; * renal replacement; * history of drug or alcohol abuse; * night- or shift-work employment; * treatment with steroids or hormonal therapy; * acute changes in eGFR \>30% in the past 3 months; * presence of acquired immunodeficiency syndrome; * CV disorders (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure,and grade III or IV retinopathy); * intolerance to ambulatory BP monitoring (ABPM); * inability to communicate and comply with all of the study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| renal events and Cardiovascular events | 5 years | doubled creatine or renal replacement, myocardial infarction, heart failure, stroke, vascular reconstruction, peripheral vascular disease, non-traumatic amputation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| proteinuria | 5 years | 24h proteinuria \>1g |
| renal function | 5 years | eGFR\<30ml/min/1.73m2 |
| Thickness of the medial membrane of the carotid artery | 5 years | cIMT \>1mm |
| Left ventricle weight index | 5 years | LVMI \>115g/m2 (man) 和 \>95g/m2 (woman) |
Contacts
Primary ContactCheng Wang, Doctor
Backup ContactYe Zhu, Doctor
Outcome results
None listed